Lung Cancer
Conditions
Keywords
stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Brief summary
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IIIB or stage IV non-small cell lung cancer who have finished first-line chemotherapy.
Detailed description
OUTLINE: This is a multicenter study. * Phase I (single site \[University of Miami Sylvester Comprehensive Cancer Center\]): Patients receive allogeneic B7.1 and human leukocyte antigen-A1 (HLA-A1) transfected tumor cell vaccine intradermally (ID) in weeks 1, 3, and 5. Treatment repeats every 6 weeks for 2 courses. If no more than 1 of 6 patients experience a probable or definitively treatment related adverse effect (i.e., grade 2 autoimmune or grade 3-4 of any type), patients proceed to the phase II portion of the study. If 2 or more (out of 6) patients experience treatment related adverse effects the study stops. * Phase II (randomized): Patients are stratified according to study site (University of Miami Sylvester Comprehensive Cancer Center or Memorial Regional Hospital), type of prior first-line treatment (platinum and taxane vs platinum and gemcitabine), and presence of brain metastasis (yes vs no). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive allogeneic B7.1 and HLA-A1 transfected tumor cell vaccine ID in weeks 1, 3, and 5. Treatment repeats every 6 weeks for 2 courses. * Arm II: Patients receive a placebo vaccine as in arm I. Patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for cluster of differentiation 8 (CD8), cluster of differentiation 4 (CD4), and natural killer cell (NK) response and peripheral blood lymphocytes (PBL) and T helper cell 1 (TH1)/T helper cell 2 (TH2) bias, including levels of interleukin (IL) IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, Interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) via ELISA. After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 4 years, and then once a year thereafter. PROJECTED ACCRUAL: A total of 66 patients (6 patients for phase I and 60 patients for phase II) will be accrued for this study.
Interventions
BIOLOGICALAllogeneic B7.1/HLA-A1
Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
OTHERPlacebo
Given intradermally
Sponsors
University of Miami
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with stage IIIB (non-candidates for radiation) or stage IV pathologically confirmed non-small cell carcinoma of the lung that completed 4-6 cycles of platinum based first line chemotherapy and achieved complete response (CR), partial response (PR) or stable disease. * Last administration of chemotherapy occurred no later than 4 weeks prior to the enrollment date. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Renal Requirements: The calculated creatinine clearance must be at least 50 ml/min. * Pulmonary Function Requirements: * All patients will undergo evaluation of pulmonary function prior to enrollment. * Patients should have a Forced expiratory volume in 1 second (FEV1) more than 30% of the predicted value and/or Diffusing capacity (DLCO) more than 30% of the predicted value with a partial pressure of carbon dioxide (PCO2) \< 45mm. * Any patient enrolled in the protocol whose respiratory symptoms have experienced marked deterioration not related to a known cause (e.g. pneumonia, congestive heart failure (CHF) or pulmonary embolism (PE)) will have request pulmonary function test (PFT) evaluation and if the above parameters are seen will be excluded from the protocol. * Age ≥ 18 years. * Signed informed consent. * Patients should have absolute neutrophil count (ANC) ≥ 1000/mm3; platelets (PLT) ≥ 80,000/mm3.
Exclusion criteria
* Small cell carcinoma of the lung. * Existing autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease etc; colitis, inflammatory bowel disease or pancreatitis within 10 years of study. * Other active malignancies present within the past three years, except for basal and/or squamous cell carcinoma(s) or in situ cervical cancer. * Concomitant steroid or other immunosuppressive therapy. * Active infection, or less than 7 days since therapy for acute infections. * Pericardial effusion. * Currently receiving chemotherapy for another condition (such as arthritis). * Time elapsed greater than 4 weeks since last administration of first line chemotherapy for NSCLC. * Active or symptomatic cardiac disease such as congestive heart failure, angina pectoris or recent myocardial infarction. * Pregnant or lactating women (negative test for pregnancy required of women of childbearing potential). * Refusal in fertile men or women to use effective birth control measures during and for six months after the completion of treatment on study. * Known HIV infection * Untreated or uncontrolled brain metastasis. * Liver Enzymes greater than 3 times the institutional upper limit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Preliminary Safety Profile (Phase 1) | Up to 13 weeks | This will include the number of patients experiencing toxicity over the course of treatment, characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination. |
| Progression-free Survival (Phase 2) | Date of randomization to the earliest date of documented progression. | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Profile (Phase 2) | About 13 weeks | The rate of patients experiencing toxicity over the course of treatment will be characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination. |
| Response to Second-line Chemotherapy After Disease Progression (Phase 2) | From Week 1 of Study Therapy until Death or Withdrawal of Consent | The percentage of patients experiencing a clinical response (complete response (CR), partial response (PR), stable disease (SD)) on second-line chemotherapy will be characterized for B7-vaccinated patients and controls. |
| Immune Response (CD8) in B7-vaccinated Participants as Compared to Controls. (Phase 2) | About 13 weeks | Rate of immune response (CD8) in B-7 vaccinated participants reported for measurements taken immediately prior to vaccination (week 0) and throughout the two courses. |
| Correlative Immunological Studies in Study Participants (Phase 2) | Baseline, Week 7 and Week 13 | The time course of patients' adaptive immune response to B7 vaccination as compared to control vaccine will be characterized by their CD8, CD4, and NK response (measured by ELI-spots for interferon-gamma (IFN-γ), interleukin 4 (IL-4), and granzyme B secretion) measured prior to vaccination (i.e. at baseline) and over two courses of vaccination (measurements at week 7 and 13). |
| Overall Survival (Phase 2) | Date of randomization to the recorded date of death | The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that study participants are still alive. |
| Relationship of CD8 Response in B7-vaccinated Patients to Their Progression-free Survival.(Phase 2) | From Week 1 of Study Therapy until Death or Withdrawal of Consent | Relationship of CD8 response in B7-vaccinated patients to their progression-free survival. Summarized by the median and range of follow up time for patients grouped according to disease status (progression/no progression) and vital status (died/alive at last contact). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I Patients will receive B7 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
Given intradermally. | 1 |
| Total | 1 |
Baseline characteristics
| Characteristic | Arm I |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 1 |
| serious Total, serious adverse events | 1 / 1 |
Outcome results
Primary
Preliminary Safety Profile (Phase 1)
This will include the number of patients experiencing toxicity over the course of treatment, characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination.
Time frame: Up to 13 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Preliminary Safety Profile (Phase 1) | 1 participants |
Primary
Progression-free Survival (Phase 2)
Time frame: Date of randomization to the earliest date of documented progression.
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.
Secondary
Correlative Immunological Studies in Study Participants (Phase 2)
The time course of patients' adaptive immune response to B7 vaccination as compared to control vaccine will be characterized by their CD8, CD4, and NK response (measured by ELI-spots for interferon-gamma (IFN-γ), interleukin 4 (IL-4), and granzyme B secretion) measured prior to vaccination (i.e. at baseline) and over two courses of vaccination (measurements at week 7 and 13).
Time frame: Baseline, Week 7 and Week 13
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.
Secondary
Immune Response (CD8) in B7-vaccinated Participants as Compared to Controls. (Phase 2)
Rate of immune response (CD8) in B-7 vaccinated participants reported for measurements taken immediately prior to vaccination (week 0) and throughout the two courses.
Time frame: About 13 weeks
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.
Secondary
Overall Survival (Phase 2)
The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that study participants are still alive.
Time frame: Date of randomization to the recorded date of death
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.
Secondary
Relationship of CD8 Response in B7-vaccinated Patients to Their Progression-free Survival.(Phase 2)
Relationship of CD8 response in B7-vaccinated patients to their progression-free survival. Summarized by the median and range of follow up time for patients grouped according to disease status (progression/no progression) and vital status (died/alive at last contact).
Time frame: From Week 1 of Study Therapy until Death or Withdrawal of Consent
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.
Secondary
Response to Second-line Chemotherapy After Disease Progression (Phase 2)
The percentage of patients experiencing a clinical response (complete response (CR), partial response (PR), stable disease (SD)) on second-line chemotherapy will be characterized for B7-vaccinated patients and controls.
Time frame: From Week 1 of Study Therapy until Death or Withdrawal of Consent
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.
Secondary
Safety Profile (Phase 2)
The rate of patients experiencing toxicity over the course of treatment will be characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination.
Time frame: About 13 weeks
Population: This was an outcome measure for the Phase 2 portion of the study, which was never opened to accrual. No participants were enrolled in Phase 2 therefore no data were available.